Anti-HER2 antibody toxin conjugate - TopoTarget

Drug Profile

Anti-HER2 antibody toxin conjugate - TopoTarget

Alternative Names: Zemab

Latest Information Update: 16 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Developer TopoTarget
  • Class Antineoplastics; Immunotoxins
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2010 No development reported - Phase-I for Cancer in Denmark (Intratumoural)
  • 15 May 2007 Phase-I clinical trials in Cancer in Denmark (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top